Dineshsinha Chauhan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dineshsinha Chauhan has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- John J. Turchi
Department of Medicine, Indiana University School of Medicine
2 shared publications - Narva Deshwar Kushwaha
Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences (EACPHS), Wayne State University, Detroit, MI 48201, USA
2 shared publications - Navnath S. Gavande
Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences (EACPHS), Wayne State University, Detroit, MI 48201, USA
2 shared publications - Pamela L. Mendoza-Munoz
Department of Medicine, Indiana University School of Medicine (IUSM), Indianapolis, IN 46202, USA
2 shared publications Hariprasad Aruri
Department of Pharmaceutical Sciences, Wayne State University College of Pharmacy and Health Sciences, Detroit, MI 48201, USA
1 shared publication- Jean-Baptiste Charbonnier
Université Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC), Gif-sur-Yvette, France
1 shared publication
Latest Publications
- Open Access
- 3 September 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Structure-Based Design and Development of 2-Oxindole Derivatives as Next Generation Ku-DNA Binding Inhibitors (Ku-DBi’s) for Cancer Therapy.
The Ku70/Ku80 heterodimer (Ku) plays a key role in the non-homologous end joining (NHEJ) pathway by recognizing DNA double-strand breaks (DSBs) and recruiting DNA-PKcs to initiate DNA repair. Aberrant activation of this pathway contributes to therapy resistance in cancer by enhancing DNA repair capacity. Although DNA-PK inhibitors show strong in vitro potency, their clinical advancement has been hindered by poor selectivity, low tumor accumulation, and systemic toxicity, preventing the achievement of maximum tolerated doses. To address these limitations, we targeted the Ku-DNA interaction and were the first to develop Ku-DNA binding inhibitors (Ku-DBi’s) that block the Ku70/Ku80 interaction with DNA, thereby inhibiting DNA-PK activation and downstream repair. Our earlier Ku-DBi’s exhibited potent inhibitory activity and selectivity, but their in vivo utility was restricted by poor solubility, metabolic stability, and limited cellular permeability. In this study, we identified lead compounds with a novel 2-oxindole scaffold through iterative structure-activity relationship (SAR) optimization. This series of compounds maintained potent biochemical activity while exhibiting enhanced solubility, cellular permeability, and metabolic stability. Lead candidates 34 (GL-3395), 35 (GL-3392), 47 (GL-3367), and 53 (GL-3609) inhibited Ku-DNA binding at 1-4 µM and DNA-PK at 0.30-0.80 µM. Notably, compounds 19 (GL-3391), 35 (GL-3392), and 38 (GL-3366) exhibited significantly enhanced cellular uptake in both A549 and H460 cells under standard conditions without serum-free media. Molecular docking and in silico ADME profiling supported their favorable binding and drug-like properties. These findings offer a promising foundation for advancing Ku-DBi as an adjuvant therapy for DNA damage-based cancer treatment.
- 3 September 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessStructure-Based Design and Development of 2-Oxindole Derivatives as Next Generation Ku-DNA Binding Inhibitors (Ku-DBi’s) for Cancer Therapy.
The Ku70/Ku80 heterodimer (Ku) plays a key role in the non-homologous end joining (NHEJ) pathway by recognizing DNA double-strand breaks (DSBs) and recruiting DNA-PKcs to initiate DNA repair. Aberrant activation of this pathway contributes to therapy resistance in cancer by enhancing DNA repair capacity. Although DNA-PK inhibitors show strong in vitro potency, their clinical advancement has been hindered by poor selectivity, low tumor accumulation, and systemic toxicity, preventing the achievement of maximum tolerated doses. To address these limitations, we targeted the Ku-DNA interaction and were the first to develop Ku-DNA binding inhibitors (Ku-DBi’s) that block the Ku70/Ku80 interaction with DNA, thereby inhibiting DNA-PK activation and downstream repair. Our earlier Ku-DBi’s exhibited potent inhibitory activity and selectivity, but their in vivo utility was restricted by poor solubility, metabolic stability, and limited cellular permeability. In this study, we identified lead compounds with a novel 2-oxindole scaffold through iterative structure-activity relationship (SAR) optimization. This series of compounds maintained potent biochemical activity while exhibiting enhanced solubility, cellular permeability, and metabolic stability. Lead candidates 34 (GL-3395), 35 (GL-3392), 47 (GL-3367), and 53 (GL-3609) inhibited Ku-DNA binding at 1-4 µM and DNA-PK at 0.30-0.80 µM. Notably, compounds 19 (GL-3391), 35 (GL-3392), and 38 (GL-3366) exhibited significantly enhanced cellular uptake in both A549 and H460 cells under standard conditions without serum-free media. Molecular docking and in silico ADME profiling supported their favorable binding and drug-like properties. These findings offer a promising foundation for advancing Ku-DBi as an adjuvant therapy for DNA damage-based cancer treatment.
- Open Access
Impact of Optimized Ku–DNA Binding Inhibitors on the Cellular and In Vivo DNA Damage Response
Background: DNA-dependent protein kinase (DNA-PK) is a validated cancer therapeutic target involved in DNA damage response (DDR) and non-homologous end-joining (NHEJ) repair of DNA double-strand breaks (DSBs). Ku serves as a sensor of DSBs by binding to DNA ends and activating DNA-PK. Inhibition of DNA-PK is a common strategy to block DSB repair and improve efficacy of ionizing radiation (IR) therapy and radiomimetic drug therapies. We have previously developed Ku–DNA binding inhibitors (Ku-DBis) that block in vitro and cellular NHEJ activity, abrogate DNA-PK autophosphorylation, and potentiate cellular sensitivity to IR. Results and Conclusions: Here we report the discovery of oxindole Ku-DBis with improved cellular uptake and retained potent Ku-inhibitory activity. Variable monotherapy activity was observed in a panel of non-small cell lung cancer (NSCLC) cell lines, with ATM-null cells being the most sensitive and showing synergy with IR. BRCA1-deficient cells were resistant to single-agent treatment and antagonistic when combined with DSB-generating therapies. In vivo studies in an NSCLC xenograft model demonstrated that the Ku-DBi treatment blocked IR-dependent DNA-PKcs autophosphorylation, modulated DDR, and reduced tumor cell proliferation. This represents the first in vivo demonstration of a Ku-targeted DNA-binding inhibitor impacting IR response and highlights the potential therapeutic utility of Ku-DBis for cancer treatment.
Open AccessImpact of Optimized Ku–DNA Binding Inhibitors on the Cellular and In Vivo DNA Damage Response
Background: DNA-dependent protein kinase (DNA-PK) is a validated cancer therapeutic target involved in DNA damage response (DDR) and non-homologous end-joining (NHEJ) repair of DNA double-strand breaks (DSBs). Ku serves as a sensor of DSBs by binding to DNA ends and activating DNA-PK. Inhibition of DNA-PK is a common strategy to block DSB repair and improve efficacy of ionizing radiation (IR) therapy and radiomimetic drug therapies. We have previously developed Ku–DNA binding inhibitors (Ku-DBis) that block in vitro and cellular NHEJ activity, abrogate DNA-PK autophosphorylation, and potentiate cellular sensitivity to IR. Results and Conclusions: Here we report the discovery of oxindole Ku-DBis with improved cellular uptake and retained potent Ku-inhibitory activity. Variable monotherapy activity was observed in a panel of non-small cell lung cancer (NSCLC) cell lines, with ATM-null cells being the most sensitive and showing synergy with IR. BRCA1-deficient cells were resistant to single-agent treatment and antagonistic when combined with DSB-generating therapies. In vivo studies in an NSCLC xenograft model demonstrated that the Ku-DBi treatment blocked IR-dependent DNA-PKcs autophosphorylation, modulated DDR, and reduced tumor cell proliferation. This represents the first in vivo demonstration of a Ku-targeted DNA-binding inhibitor impacting IR response and highlights the potential therapeutic utility of Ku-DBis for cancer treatment.